Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Non-Current Deffered Revenue (2017 - 2025)

Assembly Biosciences has reported Non-Current Deffered Revenue over the past 9 years, most recently at $1.7 million for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue fell 94.72% year-over-year to $1.7 million; the TTM value through Sep 2025 reached $1.7 million, down 94.72%, while the annual FY2024 figure was $35.4 million, 36.12% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $1.7 million at Assembly Biosciences, down from $13.0 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $55.4 million in Q4 2023 and troughed at $1.7 million in Q3 2025.
  • A 5-year average of $13.9 million and a median of $2.7 million in 2021 define the central range for Non-Current Deffered Revenue.
  • Biggest five-year swings in Non-Current Deffered Revenue: skyrocketed 1926.31% in 2023 and later plummeted 94.72% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $2.7 million in 2021, then changed by 0.0% to $2.7 million in 2022, then skyrocketed by 1926.31% to $55.4 million in 2023, then plummeted by 36.12% to $35.4 million in 2024, then plummeted by 95.15% to $1.7 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for ASMB at $1.7 million in Q3 2025, $13.0 million in Q2 2025, and $22.8 million in Q1 2025.